Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Abivax SA (ABVX) - Total Liabilities
Latest total liabilities as of September 2025: €140.81 Million EUR
Based on the latest financial reports, Abivax SA (ABVX) has total liabilities worth €140.81 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abivax SA - Total Liabilities Trend (2013–2024)
This chart illustrates how Abivax SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Abivax SA Competitors by Total Liabilities
The table below lists competitors of Abivax SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Dahua Technology Co Ltd
SHE:002236
|
China | CN¥13.12 Billion |
|
NKT A/S
PINK:NRKBF
|
USA | $3.66 Billion |
|
HUB24 Ltd
AU:HUB
|
Australia | AU$132.53 Million |
|
Dixon Technologies (India) Limited
NSE:DIXON
|
India | ₹149.67 Billion |
|
UPL Limited
NSE:UPL
|
India | ₹536.81 Billion |
|
Telephone and Data Systems Inc
NYSE:TDS
|
USA | $3.25 Billion |
|
Texas Capital Bancshares Inc
NASDAQ:TCBI
|
USA | $27.91 Billion |
|
Shenzhen Transsion Holdings Co Ltd
SHG:688036
|
China | CN¥27.75 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Abivax SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abivax SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abivax SA (2013–2024)
The table below shows the annual total liabilities of Abivax SA from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €164.64 Million | +25.63% |
| 2023-12-31 | €131.05 Million | +83.37% |
| 2022-12-31 | €71.47 Million | -12.40% |
| 2021-12-31 | €81.59 Million | +22.46% |
| 2020-12-31 | €66.62 Million | +66.78% |
| 2019-12-31 | €39.95 Million | +105.98% |
| 2018-12-31 | €19.39 Million | +244.17% |
| 2017-12-31 | €5.63 Million | +45.23% |
| 2016-12-31 | €3.88 Million | -14.35% |
| 2015-12-31 | €4.53 Million | +12.38% |
| 2014-12-31 | €4.03 Million | -9.29% |
| 2013-12-31 | €4.44 Million | -- |